A prospective, single center, open, comparative, pilot clinical trial to evaluate the efficacy and safety of anti-adhesive agent Interguard® in patients undergoing abdominal surgery

Abstract Purpose: We performed a prospective study to assess whether the use adhesion barrier Interguard® reduces the rate of adhesion grade in patients who undergoing colorectal surgery plus temporary loop ileostomy as compared to that of the no additive control group.Methods: A total of 38 patients were enrolled between May 2019 and July 2020.Among the 38 enrolled patients, 14 patients received Interguard®, and 24 patients received no additive.Results There was no significant difference of the baseline characteristics between each group. There were no significant differences between the groups for the type of operation (P = 0.163). Operation time was not significantly different between the two groups (P = 0.471). The blood laboratory data was not significantly different from day 5 and 7. None of the patients experienced wound infection and/or anastomotic leakage. None of the patients in Interguard® group developed small bowel ileus after the ileostomy takedown. Adhesion score less than 5 was significantly lower in Interguard® group as compared to control group (P = 0.001). Lower abdomen adhesion score was significantly higher in control group (P = 0.009)ConclusionsThe application of Interguard® did reduce the adhesion grade in patients who were undergoing colorectal surgery and temporary ileostomy as compared to the control group.